FDA Hears Wide Debate On Generic-Drug Warning Label Plan
Drugmakers, lawyers and consumers on Friday debated the U.S. Food and Drug Administration's controversial plan to let generic-drug makers independently update their warning labels, trading divergent views on how patient safety...To view the full article, register now.
Already a subscriber? Click here to view full article